Sacubitril-Valsartan Reasonably Cost-Effective in Heart Failure

Share this content:
Sacubitril-Valsartan Reasonably Cost-Effective in Heart Failure
Sacubitril-Valsartan Reasonably Cost-Effective in Heart Failure

TUESDAY, Aug. 30, 2016 (HealthDay News) -- For patients with heart failure with reduced ejection fraction, sacubitril-valsartan is cost-effective for reducing cardiovascular mortality and morbidity, according to a study published online Aug. 30 in the Annals of Internal Medicine.

Alexander T. Sandhu, M.D., from the Veterans Affairs Palo Alto Health Care System in California, and colleagues designed a Markov decision model to examine the cost-effectiveness of sacubitril-valsartan versus angiotensin-converting enzyme inhibitor therapy in patients with chronic heart failure. The target population was made up of patients (average age, 64 years) with New York Heart Association (NYHA) class II to IV heart failure, and a left ventricular ejection fraction of 0.40 or less.

The researchers found that the sacubitril-valsartan group experienced 0.08 fewer heart failure hospitalizations, 0.69 additional life-years, 0.62 additional quality-adjusted life-years (QALYs), and $29,203 in incremental costs, for a cost of $47,053 per QALY gained in the base-case analysis. In patients with NYHA class II heart failure and NYHA class III or IV heart failure, the cost per QALY gained was $44,531 and $58,194, respectively. In sensitivity analysis, treatment was most sensitive to the duration of improved outcomes, with a cost of $120,623 per QALY gained if the duration was limited to the length of the trial (median, 27 months).

"Treatment with sacubitril-valsartan provides reasonable value in reducing cardiovascular mortality and morbidity in patients with NYHA class II to IV heart failure," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novartis, which manufactures sacubitril-valsartan.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »